Voyager Therapeutics Inc (VYGR) to Post Q1 2017 Earnings of ($0.46) Per Share, Wedbush Forecasts
Voyager Therapeutics Inc (NASDAQ:VYGR) – Wedbush reduced their Q1 2017 EPS estimates for shares of Voyager Therapeutics in a note issued to investors on Thursday. Wedbush analyst D. Nierengarten now expects that the brokerage will earn ($0.46) per share for the quarter, down from their prior estimate of ($0.39). Wedbush currently has a “Outperform” rating and a $36.00 target price on the stock. Wedbush also issued estimates for Voyager Therapeutics’ Q2 2017 earnings at ($0.52) EPS, Q3 2017 earnings at ($0.58) EPS, Q4 2017 earnings at ($0.65) EPS, FY2017 earnings at ($2.21) EPS, FY2018 earnings at ($2.80) EPS, FY2019 earnings at ($3.18) EPS, FY2020 earnings at ($3.42) EPS and FY2021 earnings at ($2.56) EPS.
Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Wednesday, March 15th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.11. Voyager Therapeutics had a negative return on equity of 20.58% and a negative net margin of 195.31%.
Your IP Address:
A number of other equities analysts have also commented on VYGR. Chardan Capital set a $11.00 price objective on Voyager Therapeutics and gave the stock a “hold” rating in a research note on Thursday, December 8th. Cowen and Company reiterated a “buy” rating on shares of Voyager Therapeutics in a research note on Thursday, December 8th. Zacks Investment Research downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 18th. Nomura began coverage on Voyager Therapeutics in a research report on Wednesday, March 1st. They set a “buy” rating on the stock. Finally, Instinet began coverage on Voyager Therapeutics in a research report on Wednesday, March 1st. They set a “buy” rating and a $31.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $27.50.
Shares of Voyager Therapeutics (NASDAQ:VYGR) opened at 11.45 on Monday. The stock’s 50 day moving average price is $12.37 and its 200-day moving average price is $12.64. Voyager Therapeutics has a 12 month low of $8.30 and a 12 month high of $18.25. The firm’s market capitalization is $305.94 million.
A number of large investors have recently added to or reduced their stakes in the company. Harbourvest Partners LLC purchased a new stake in Voyager Therapeutics during the fourth quarter worth $463,000. State Street Corp increased its stake in Voyager Therapeutics by 5.3% in the fourth quarter. State Street Corp now owns 165,503 shares of the company’s stock worth $2,108,000 after buying an additional 8,257 shares during the period. Bessemer Group Inc. purchased a new stake in Voyager Therapeutics during the fourth quarter worth $278,000. Aberdeen Asset Management PLC UK purchased a new stake in Voyager Therapeutics during the fourth quarter worth $177,000. Finally, Russell Investments Group Ltd. purchased a new stake in Voyager Therapeutics during the fourth quarter worth $194,000. 39.95% of the stock is currently owned by institutional investors and hedge funds.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
Receive News & Stock Ratings for Voyager Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc and related stocks with our FREE daily email newsletter.